Andrzej Jakubowiak, MD

Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System.
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System. J Appl Lab Med. 2024 Dec 19.
PMID: 39699179

Germline predisposition in multiple myeloma.
Germline predisposition in multiple myeloma. iScience. 2025 Jan 17; 28(1):111620.
PMID: 39845416

A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma. Future Oncol. 2025 Jan; 21(1):25-49.
PMID: 39452950

Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma.
Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma. EJHaem. 2024 Dec; 5(6):1260-1264.
PMID: 39691273

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 10 07; 14(1):170.
PMID: 39375362

Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication.
Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication. Oncologist. 2024 Sep 06; 29(9):806-810.
PMID: 38920281

Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood. 2024 08 29; 144(9):955-963.
PMID: 38713888

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat Genet. 2024 Sep; 56(9):1878-1889.
PMID: 39160255

Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy.
Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy. Blood Adv. 2024 07 23; 8(14):3785-3797.
PMID: 38810262

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood Cancer J. 2024 07 08; 14(1):107.
PMID: 38977707